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Introduction
Bisphosphonates	 represent	 the	 category	
of	 drugs	 most	 commonly	 used	 in	 the	 treatment	
of	 osteoporosis	 in	 postmenopausal	 women	
with	 this	 disease	 (Melton	 et al.,	 1992),	 as	 well	
as	 in	 the	 treatment	 of	 bone	 metastases	 in	
prostate	 carcinomas	 (Coxon	 et al.,	 2004),	 bone	
metastases	 in	 multiple	 myeloma	 (Berenson,	
1996;	Hortobagyi	et al.,	2007),	patients	receiving	
high-dose	 corticosteroids	 for	 various	 conditions	
(Graham,	 1992),	 and	 according	 to	 new	 studies,	
can	 also	 be	 administered	 to	 children	 with	
imperfect	osteogenesis	(Graham,	1992).	The	bone	
is	 continuously	 trained	 throughout	 life,	 being	
constantly	 changing.	There	 is	 a	 constant	balance	
between	 bone	 resorption	 and	 bone	 recovery,	
aided	 by	 osteoblast	 cells	 and	 osteoclasts.	 When	
this	 balance	 is	 disturbed	 by	 systemic	 diseases	
(osteoporosis),	there	are	changes	in	bone	geometry	
(at	the	level	of	hydroxyapatite).	Osteoblasts	form	
a	 bone	 matrix	 (collagen	 or	 non-collagen)	 called	
osteoid.	They	can	remain	on	the	bone	surface	by	
performing	bone	apoptosis	(Tripton	et al.,	2010).	
Osteoclasts	 are	 formed	 from	 hematopoietic	 cells	
of	 monocytes	 or	 macrophages.	 During	 bone	
resorption,	 hydroxyapatite	 and	 organic	 matrix	
are	 removed	 by	 the	 multinucleated	 osteoclasts.	
Both	 bone	 deposition	 and	 bone	 resorption	 are	
coordinated	 and	 controlled	 by	 endocrine	 and	
biological	 mediators	 mediating	 stimulation	
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(Parathyroid	 Hormon	 PTH,	 Parathyroid-related	
peptide	 Rpth,	 Prostaglandine	 E2,	 Vitamin	 D3)	
and	 inhibition	 (Calcitonin,	 Estrogen,	 Interferon,	
Transforming	growth	factor	B)	(Frank	et al.,	2001;	
Lewiecki,	 2010).	 Bone	 metabolism	 is	 regulated	
by	 RANK	 (receptor-activated	 nuclear	 factor	 Kβ),	
RANKL	 (receptor-activated	 nuclear	 factor	 Kβ	
ligand)	 and	 OPG	 (osteoprotegrin).	 The	 balance	
between	RANKL	and	OPG	is	crucial	in	the	control	
of	 osteoclasts	 in	 the	 bone	 microclimate.	 RANK	
is	 expressed	 in	 the	 cell	 membrane	 plasma	 of	
osteoclasts,	 RANKL	 is	 expressed	 in	 the	 cellular	
plasma	membrane	plasma	of	osteoblasts	and	OPG	
is	 produced	 by	 osteoblasts	 acting	 as	 a	 receptor	
decoding	 its	 RANKL	 binding,	 thus	 preventing	
RANK	action	(Sarina	et al.,	2010).
Osteoporosis	is	defined	as	a	bone	cell	disorder	
characterized	 by	 a	 decrease	 in	 bone	 mass	 and	
bone	 tissue	 integrity,	 resulting	 in	 frailty	 and	
decreased	bone	hardness.	 This	 decrease	 in	 bone	
cell	 performance	 leads	 to	 an	 increased	 risk	 of	




estrogen	 deficiency	 is	 the	 main	 contributing	
factor	 in	 the	 formation	 of	 osteoporosis	 in	 both	
women	 and	 men	 (McClung	 et al.,	 2006).	 The	
estrogen	 deficiency	 present	 at	 an	 advanced	 age	





ligand	 RANKL	 /	 Osteoprotegerin	 (OPG)	 triggers	
an	 important	 signal	 that	 regulates	 osteoclast	
formation.	 Thus,	 the	 RANK	 /	 RANKL	 binding	
inhibits	 the	 formation	 and	 differentiation	 of	
osteoclasts	 and	 implicitly	 slows	 bone	 resorption	
(Bone	 et al.,	 2008).	 Recent	 studies	 have	 shown	
that	 regulation	 of	 bone	 cell	 RANKL	 activity	 and	
estrogen	 deficiency	 in	 postmenopausal	 women	
are	responsible	for	bone	resorption	(Frank	et al.,	
2001;	 Miller	 et al.,	 2010).	 	 Furthermore,	 some	
experiments	 performed	 on	 the	 animal	 model	
(ovariectomized	mice)	to	induce	osteoporosis	have	
shown	 that	 OPG,	 in	 addition	 to	 preventing	 bone	
resorption,	 also	 increases	 bone	 mineral	 density,	
excessively	 leading	 to	 osteopetrosis.	 It	 has	 been	
demonstrated	that	a	single	dose	of	OPG	injectable	
in	postmenopausal	women	may	result	 in	a	 rapid	
and	 profound	 reduction	 in	 bone	 turnover	 over	
even	12	hours;	This	fact	could	be	demonstrated	by	
biochemical	markers	and	collagen	products	(NTX	
urinary	 N-telopeptide,	 DPD	 deoxypyridinoline)	
(Dilep	et al.,	2013;	Petcu	et al.,	2013).
The	mechanism	of	action	of	bisphosphonates	
is	 not	 fully	 understood.	 According	 to	 research	
conducted	 so	 far,	 bisphosphonates	 can	 induce	
apoptosis	in	osteoclasts.	Injectable	bisphosphonate	
formulations	 have	 direct	 action	 on	 osteocytes,	
producing	 their	 lysis.	 Bisphosphonates	 alter	
the	 production	 of	 RANKL	 and	 OPG,	 leading	 to	 a	





marked	 osteoblast	 activity)	 and	 low	 calcium	
absorption	in	bone	hydroxyapatite	(osteoporosis).	
These	 include	 etidronate,	 clodronate	 and	
pamidronate.	 Over	 the	 years	 and	 research	 in	
this	 field	 has	 evolved,	 the	 same	 category	 of	
pharmaceuticals	 and	 nonidronate,	 risendronate,	
zolendronate,	 minodronate,	 alendronate	 and	
ibandronate	(Marx	et al.,	2003)	have	joined.	Since	
only	 two	 types	 of	 bisphosphonates	 (ibandronic	
acid	 and	 denosumab)	 have	 been	 used	 in	 the	
present	 study,	 I	will	 continue	 to	discuss	 some	of	
the	literature	on	this	issue.
Denosumab,	 from	a	molecular	point	of	 view,	
is	 a	 human	 monoclonal	 antibody	 that	 acts	 by	
inhibiting	 RANK	 NF-kβ	 ligand	 RANKL,	 being	
a	 cytokine	 of	 the	 TNF	 family	 and	 the	 primary	
mediator	 of	 bone	 resorption	 (osteoclasts).	 By	
linking	 to	 RANKL,	 Denosumab	 prevents	 RANK	
activation.	This	phenomenon	leads	to	inhibition	of	
osteoclast	maturation,	 decrease	 in	 their	 function	
and	 subsequently	 inhibition	 of	 bone	 resorption	
(Bilezikian	2006;	Federico	et al., 2001).	Clinically,	
patients	 are	 given	 subcutaneous	 injection	 two	
times	 every	 6	 months	 at	 a	 dose	 of	 60-120	 mg	
(Torres	 et al., 2011;	 Yamashita	 et al., 2012).	 Its	
effect	 translates	 into	 a	 significant	 and	 rapid	
reduction	 in	 bone	 turnover	 associated	 with	 a	






have	 been	 exposed	 previously.	 Risk-related,	 like	
COLIBABA et al
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any	drug,	bisphosphonates	also	have	side	effects	
such	 as	 burning	 sensation,	 erosive	 esophagitis	
associated	with	dysphagia,	oesophageal	 stenosis,	
uveitis,	 gastric	 ulceration	 and	 abdominal	 pain,	
oesophageal	 mucosal	 ulceration.	 When	 pseudo-
flue	 syndrome	 (ie	 fever,	 chills,	 myalgia,	 atralgia,	
bone	 pain),	 phlebitis,	 anemia,	 fatigue,	 general	
weakness,	 edema,	 dyspnea	 (Nicolau	 et al.,	 2012;	
Whute	 2010;	Wilfried	 et al.,	 2005-2006)	 occurs,	
it	 is	 recommended	 that	 the	patient	 receiving	 the	
bisphosphonate	treatment	to	be	monitored	by	the	
treating	physiciant.	The	most	common	complication	
is	 bone	 necrosis	 localized	 predominantly	 in	 the	
jaw	bone	 (ONJ).	This	pathological	entity	appears	
in	 a	 very	 large	 percentage	 at	 patients	 receiving	
intravenous	bisphosphonate	therapy	(Paula	et al., 
2012;	Sanna	et al., 2006).	These	issues	raised	great	




biomechanical	 skills,	 tissue	 dehiscence,	 chronic	
bone	 dehiscence,	 hypocellularity,	 radiologically	
observed	 bone	 lysis	 (Lab.Corp.America	 2010;	
Fischbach	 2009)	 localized	 to	 the	 jaw	 bone,	
mandibular	 or	 palate	 with	 a	 Delayed	 or	 non-
healing	for	a	period	of	6-8	weeks	(Wallach	2001;	




or	 other	 alveolar	 dental	 surgery	 (Lothan	 1998).	
The	 BRONJ	 is	 not	 a	 new	 pathological	 entity;	 In	
the	 past,	 the	 development	 of	 mandibular	 bone	
lesions	 has	 been	 associated	with	 head	 and	 neck	
irradiation,	osteomyelitis	and	even	corticosteroid	
treatment	(Wallach	2001;	Franketal	et al.,	2012).
For	 clear	 and	 accurate	 screening	 of	 the	
BRONJ	 and	 its	 stages	 of	 development,	 X-ray	
(OPT,	 Panoramic	 X-ray)	 is	 used	 where	 thick	
lamellar	 thickening,	 osteosclerosis,	 osteolysis,	
diffuse	 sclerosis,	 subperiosteal	 bone	 deposits,	
postoperative	 bone	 remodeling	 (Pighon	 et al., 
2010;	Sankar	et al.,	2014;	Lazar	et al.,	2016),	CBCT	
(ComputerTomography),	 their	 major	 advantage	
is	the	3D	access	of	bone	structures	at	a	very	good	
resolution.	 Radiation	 exposure	 is	 higher	 than	 at	
OPT,	but	lower	than	MSTT	(Multisliced		Computer	
Tomography)	 (Pighon et al.,	2010).	A	correlation	
between	the	two	related	to	sensitivity	in	the	ONJ	





The	 present	 study	 aims	 to	 expose	 an	
experimental	 comparison	 done	 on	 the	 animal	
model	 -	 females	 wistar	 mice	 -	 between	 two	
types	 of	 bisphosphonates	 (ibandronic	 acid	 and	
denosumab),	 in	 the	 conditions	 of	 osteoporosis	
induced	 by	 ovariectomy,	 performing	 extractions	




effect	 of	 the	 administration	 of	 bisphosphonates	
under	 the	 conditions	 of	 dental	 extractions.	 The	
results	 obtained	 come	 to	 the	 help	 of	 dental	
practitioners	 who	meet	 in	 current	 practice	 with	
patients	 with	 osteoporosis	 who	 are	 not	 only	
being	treated	or	have	completed	bisphosphonate	
treatment	 and	 the	 appropriate	 dental	 treatment	
plan	in	these	cases.
The	 purpose	 of	 this	 research	 (Lazar	 et al., 
2016)	 is	 to	 observe	 the	 positive	 and	 negative	
effects	 of	 bisphosphonates	 and	 denosumab	 on	











Females	 of	 30	 wistar	 mice	 were	 purchased	





23	 °	 C.	 All	 mice	 received	 appropriate	 nutrition	
(pellet	rat	chow)	following	the	nutritional	values	
(12%	 fat,	 63.2%	 carbohydrates,	 24.3%	 protein)	
required	for	mice	and	unlimited	access	from	fresh	
bottles	to	fresh	water	(Marx	2003).                                  
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weight	 intramuscularly.	 The	 mid-caudal	 ventral	
ventricle	of	the	third	pair	of	mammary	livers	was	
breed	and	cleansed	with	chloramine	and	alcohol	
disinfectant	 solution.	 A	 2	 cm	 incision	 (http://
www.fda.gov/downloads/	 advisorycommittees/
c omm i t t e e sme e t i n gma t e r i a l s / d r u g s /
oncologicdrugsadvisorycommittee/	 ucm250379.
pdf	.	Acessed	September	7,	2015)	was	performed,	
the	 skin	was	 separated	 from	 the	muscle	 and	 the	
ovaries	 exposed	 (Fig.	 2).	 These	 were	 extirpated	
(Fig.	3)	using	a	special	ophthalmic	catheter.	After	
removal	 of	 the	 ovaries,	 the	 peritoneum	 and	 the	
white	line	were	closed	with	a	3.0-threaded	suture	
thread	 in	 continuous	 thread	 and	 a	 4.0-threaded	
cut	 suture	 resorbable	 at	 separate	 points	 (Van	
Breukelen	1982;	Lipton	et al., 2004)	(Fig.	4).	The	
operator,	mice	were	coated	with	gauze	bandage	to	
avoid	 hypothermia	 (42)	 and	 antibiotic	 and	 anti-
inflammatory	treatment	was	administered.
The	 operative	 protocol	 was	 performed	 on	
February	 3,	 2015,	 and	 for	 a	 period	 of	 3	months	
(28	 May	 2015)	 the	 occurrence	 of	 osteoporosis	







in	 the	 humerus	 was	 observed	 in	 approximately	










































were	 taken	 from	 each	 rat	 from	 the	 infraorbital	




x-rays	 were	 performed	 in	 all	 rats.	 Subsequently,	
the	 lots	 were	 divided:	 Lot	 1	 -	 Ibandronic	 acid	
administration	 (OSAGRAND	 3mg	 /	 3ml	 single	




in	 the	 pre-filled	 syringe,	 fractionated	 0.025	 ml	
denosumab	salt,	0.125	ml	physiological	saline	so	
that	One	0.150	ml	was	administered	to	each	rat),	




Twenty	 days	 after	 the	 first	 radiological	
exposure,	 a	 new	 set	 of	 blood	 and	 radiological	
assays	 was	 performed	 to	 benchmark	 these	
parameters.	Dental	extractions	 (extraction	of	 the	
upper	central	incisor	/	rat)	were	performed	every	
20	days	in	each	batch	of	rats.                    
 Management of dental extraction
Sedation	 by	 intraperitoneal	 anesthesia	 with	
subst.	Xylazin	bio	2%	„,	vetased	5	mg	/	kg,	50	mg	
ketamine.	 Sindesomotomy	 was	 performed	 with	
a	 spatula	 and	 extraction	 of	 the	 upper	 central	
incisor	 by	 means	 of	 a	 small	 size	 hemostatic	
tweezer.	Suture	with	resorbable	suture	thread	5.0.	
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At	34	days	after	the	first	exposure,	a	new	set	
of	blood	and	radiological	analyzes	was	performed	
to	 detect	 the	 occurrence	 of	 osteonecrosis	 of	 the	
jaw	 bone.	 For	 this,	 inhalation	 anesthesia	 was	
performed	with	isoflurane	(5	liters	gas,	2	liters	of	
oxygen)	 in	 the	 anesthetic	 cage.	After	 performing	
routine	 analyzes,	 rats	 were	 euthanized	 by	
prolonged	exposure	to	isofluorane	until	death	was	
observed.
Results and discussions   
During	 the	 experiment,	 blood	 samples	 (PAL,	
Creatinine)	 and	 rat	 exposures	were	made.	 Thus,	
3	months	after	the	ovariectomy	procedure	of	each	
rat,	 a	 blood	 sampling	 and	 radiological	 sampling	
was	 performed	 for	 each	 rat	 in	 each	 batch.	




of	 the	 two	 types	of	bisphosphonates	 (ibandronic	











Administration	 of	 denosumab	 (Prolia)	 in	 lot	
2	 has	 oscillating	 values	 	for	 alkaline	 phosphatase	






It	 is	 noted	 that	 creatinine	 levels	 (mg	 /	 dl)	
are	 decreasing	 at	 7,	 14,	 and	 at	 30	 days	 there	 is	
a	 slight	 increase	 in	 this	 value	 under	 conditions	
of	 osteoporosis	 induced,	 which	 means	 that	 the	
administration	of	the	acid	ibandronic	also	makes	
changes	on	this	blood	sample.
Administration	 of	 denosumab	 (Prolia)	 in	
group	 2	 has	 oscillating	 levels	 of	 creatinine	 (mg	
/	 dl)	 values.	 Thus,	 7	 days	 after	 administration,	
values		higher	than	the	14-day	and	30-day	intervals	
were	recorded.
The	 control	 group	 (group	 3)	 in	 the	 case	





the	 two	 types	 of	 bisphosphonates	 (ibandronic	
acid,	 denosumab)	 administered	 under	 induced	
osteoporosis	 produce	 blood	 changes	 in	 alkaline	
phosphatase	 and	 creatinine,	 with	 changes	 in	
their	values.	From	the	radiological	point	of	view,	
the	 occurrence	 of	 bony	 callus	 formation	 was	
observed,	especially	in	the	humerus,	but	also	the	
bone	necrosis	at	 the	 level	of	 the	postextractional	
alveoli.
The	use	of	bisphosphonates	in	the	treatment	
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on	 the	 management	 of	 this	 pathological	 entity	




in	 postmenopausal	 women,	 bisphosphonates	
are	 elective	 in	 stopping	 osteoclast	 activity	
and	 implicitly	 in	 reducing	 bone	 turnover	
translated	 by	 rarefaction	 of	 bone	 architecture.	
Their	 administration	 i.v	 has	 both	 strengths	
and	 disadvantages	 (Coxon	 et al., 2004;	 Malden	
2007;	Graham	et al.,	 2000;	Graham	et al.,	 2011).	
According	 to	 our	 experiment,	 administration	
of	 bisphosphonates	 has	 antibacterial	 effects,	
decreased	 bone	 resorption	 and,	 implicitly,	
decreased	osteoclast	activity.	This	is	beneficial	to	
postmenopausal	 osteoporosis	 patients	who	have	




Figure 22.  Creatinine - Changes at 7, 14, 30 days, group 
3 (control) on administration of physiological serum
Figure 21. Creatinine - Changes at 7, 14, 30 days, group 
2 administration of denosumab (PROLIA)
Figure 20. Creatinine - Changes at 7, 14, 30 days, group 1 
administration of Ibandronic Acid (OSAGRAND)
Figure 19. ALP (U / L) - changes at 7, 14, 30 days group 
3 on physiological serum
Figure 18. ALP (U / L) - Changes to 7, 14, 30 days, at the 
administration of denosumab group 2 (PROLIA)
Figure 17.  ALP (U / L) - Changes to 7, 14, 30 days at the 
administration of  ibandronic acid group 1 (OSAGRAND)
29




local	 bone	 necrosis.	 Thus,	 denosumab	 (PROLIA)	
is	 a	 new	 generation	 bisphosphonate	 which,	
compared	to	 ibandronic	acid,	has	beneficial	 local	
and	 general	 effects,	 the	 risk	of	 secondary	 effects	
and	complications	being	less	pronounced.
In	 our	 experiment	 on	 females	 in	 which	
osteoporosis	 was	 induced	 by	 ovariectomy,	 they	
were	divided	into	three	groups	and	then	two	types	
of	bisphosphonates	(ibandronic	acid,	denosumab)	
were	 administered,	 then	 dental	 extractions	
(extraction	 The	 upper	 central	 incisor	 for	 each	




have	 also	 been	 made	 regarding	 the	 pathogenic	
role	 of	 certain	 strains	 of	 microorganisms	 such	
as	 Actinomycetes	 and	 the	 occurrence	 of	 bone	
osteonecrosis	 (53).	 Another	 study	 on	 the	
pathogenesis	 of	 bone	 osteonecrosis	 associated	
with	 bisphosphonate	 treatment	 suggested	 that	
seminal	 soft	 tissue	 is	 affected	 semiologically.	
On	 this	 basis,	 the	 authors	 concluded	 that	 any	
bone	 injury	 caused	 by	 local	 surgical	 procedures	




                            14 days
Group 1
Mean 175.375 0.65125
Standard deviation 64.5925637 0.051944338
Group 2
Mean 189.9875 0.66125
Standard deviation 70.16711557 0.054625347
Group 3
Mean 219.2428571 0.562428571
Standard deviation 69.45019456 0.234274666
Normal values 130 0.9
Table 1.	Centralization	of	data	regarding	ALP	and	Creatinine	values;	general	normal	
values	at	7	days
                               7 days
Group 1
Mean 189.9875 0.7725
Standard deviation 42.39327566 0.091612538
Group 2
Mean 168.4375 0.85875
Standard deviation 61.24316726 0.115317884
Group 3
Mean 208.7685714 0.927142857
Standard deviation 75.68864896 0.087123339
Normal values 130 0.9
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model	could	serve	as	a	starting	point	 for	studies	





In	 the	 treatment	 of	 osteoporosis	 in	
postmenopausal	 women,	 bisphosphonates	
are	 elected	 in	 stopping	 osteoclast	 activity	
and	 implicitly	 in	 reducing	 bone	 turnover	
translated	 by	 re-shaping	 bone	 architecture.	
Their	 administration	 i.v	 has	 both	 strengths	 and	
disadvantages	 (Fleisch	 1999;	 Berston	 2000;	
Zhany	et al.,	1996;	Ridley	1992;	Frith	et al.,	2001).	
According	 to	 our	 experiment,	 administration	
of	 bisphosphonates	 has	 antibacterial	 effects,	
decreased	 bone	 resorption	 and,	 implicitly,	
decreased	 osteoclast	 activity.	 This	 is	 beneficial	
to	 postmenopausal	 osteoporosis	 patients	 who	
have	 received	 ibandronic	 acid	 or	 denosumab	
under	 dental	 surgeries	 (dental	 extractions).	 It	
has	 been	 demonstrated	 that	 denosumab	 with	
ibandronic	 acid	 has	 stronger	 antiseptic	 effects,	
and	dental	extractions	 in	 these	situations	can	be	
performed	 successfully	 without	 the	 occurrence	
of	 septic	 complications	 or	 local	 bone	 necrosis.	
Thus,	 denosumab	 (PROLIA)	 is	 a	 new	 generation	
bisphosphonate	 which,	 compared	 to	 ibandronic	




tissues.	 This	 release	 of	 bisphosphonates	 is	 toxic	
to	 the	 local	 epithelium	 and	 ultimately	 results	 in	
inhibition	of	local	cell	proliferation	and	implicitly	
a	poor	postoperative	healing.	Thus,	 these	 lesions	
provide	 an	 entry	 gate	 for	 oral	microflora,	 which	
by	local	pathologic	action	leads	to	bone	infections	
and	bone	necrosis	(Ridley	1992).	New	generation	
bisphosphonates	 by	 the	 experiment	 on	 rats	
revealed	 that	 denosumab	 (Prolia)	 has	 local	
antibacterial	 effects	 over	 other	 bisphosphonates	
(ibandronic	 acid).	 Thus,	 administration	 of	 the	
two	 types	 of	 bisphosphonates	 not	 only	 resulted	
in	 a	 decrease	 in	 bone	 marrow	 extraction,	 but	
also	 the	 thickening	 of	 the	 hard	 lamina	 with	 the	
formation	 of	 bone	 callus,	 a	 reduction	 in	 bone	
resorption,	 antibacterial	 effects	 in	 the	 dental	
extraction	conditions	and	implicitly	a	reduction	of	
the	purulent	material	at	the	level	Postextractional	




of	 bone	 osteonecrosis	 in	 rats	 with	 osteoporosis	
induced	in	which	the	two	types	of	bisphosphonates	
were	 administered	 and	 the	 monitoring	 of	
the	 biological	 and	 blood	 parameters	 in	 these	
circumstances.	 Thus,	 rats	 have	more	 accelerated	
metabolism	 than	humans,	 and	although	we	have	
noticed	 the	 beneficial	 and	 harmful	 effects	 of	




                   30 days
Group 1
Mean 168.825 0.66
Standard deviation 53.6036446 0.046904158
Group 2
Mean 157.525 0.68625
Standard deviation 80.87729242 0.071900228
Group 3
Mean 308.6714286 0.652857143
Standard deviation 132.4988517 0.054989176
Normal values 130 0.9
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